Sometimes, modern medicine is just a bet... You can lose everything if the gamble doesn't pay off. And even if you win, your doctor might not know why.

AI Is Giving This Sector New Life Joe Austin, senior analyst, Chaikin Analytics Sometimes, modern medicine is just a bet... You can lose everything if the gamble doesn't pay off. And even if you win, your doctor might not know why. And worse, far too often, doctors don't know what will happen until they start treatment. The most expensive drugs can work miracles with one patient... and do nothing for another. So as a patient, you're paying a hefty bill for something that might not even work. Take the case of Deen Allen, for example... Allen is a 59-year-old research chemist from New Jersey. He helps develop antibacterial hand soaps. And he enjoys helping middle-school students learn about math and science. For months, starting in 2011, Allen suffered from severe stomach cramps and diarrhea. He also experienced pain in his joints – especially his fingers. Doctors initially diagnosed Allen with an inflammatory bowel disease ("IBD"). An IBD is a condition where the immune system attacks the digestive tract. The most common types of IBDs are Crohn's disease and ulcerative colitis. At first, the doctors' treatment worked. Allen's symptoms went away. For about two years, he didn't have any issues. So they said he was in remission. But soon after stopping the medication, Allen's problems returned – and got worse... He would often be writhing in pain on the floor. And after dealing with these issues for a couple more years, he lost roughly 80 pounds. Doctors only figured out the real problem after Allen underwent a colonoscopy. Allen's original diagnosis was wrong. Instead, doctors discovered that he had rheumatoid arthritis. That still didn't stop the pain – or the medical bills... Even after Allen got the right diagnosis, he still faced years of trial and error with biologics. This class of drugs suppresses the immune system to reduce inflammation. Doctors put Allen on Humira. But after about a year, it no longer worked for him. Then, he tried Enbrel – which also eventually stopped working. These drugs can each cost at least $9,000 per month. That's more than $100,000 per year. Allen finally found relief with another drug, Remicade. This biologic costs anywhere from $50,000 to $150,000 per year. These drugs aren't magic elixirs. Research shows that 30% to 40% of patients quit drugs like Humira, Enbrel, and Remicade because they don't work or patients can't handle the side effects. Allen's story is about years of doctors guessing wrong – and still needing to gamble more with his treatment.  On the flip side, Sandy Doria's story is about a guess that paid off... Recommended Links: One Signal – Dozens of Massive Breakouts Seagate before a 220% surge. Palantir before a 770% rally. Carvana before a 4,400% run. Marc Chaikin and Pete Carmasino just revealed the signal that appeared before these massive winners... and recommended a stock that recently triggered the same signal. Watch the replay to get the name and ticker. An AI Play With Virtually Limitless Upside Elon Musk, Jeff Bezos, and Silicon Valley insiders have invested hundreds of billions of dollars into an AI asset that doesn't trade on the stock market. Yet, most Americans don't even know it exists! However, for those who HAVE had a chance to get in on it, it has already helped them turn $50,000 into as much as $40 million. These rare windfalls can change everything in an instant. To learn how to grab a stake in these assets, click here. This 'Last Ditch' Effort Drug Saved This Woman's Life The skincare specialist from California got married in July 2011. Just four months later, Doria learned that she had an aggressive form of breast cancer. Doctors removed the tumor. And for a while, they thought all was well. But six months later, the cancer came back. This time, it was in Doria's breast and left lung. Her cancer was triple-negative – a type that mutates and becomes especially hard to treat. Doria tried multiple treatments. Nothing worked. Eventually, tumors covered her chest. And the pain became so bad that she relied on morphine just to get through the day. Doria's doctors offered one last option. She could join a clinical trial for an experimental drug known at the time only by its lab code – MPDL-3280A. It was a long shot. But Doria was running out of time. So she had to take the gamble. Within months, Doria's tumors were gone. Unfortunately, she started suffering debilitating side effects – including a severe case of colitis. So doctors had to stop her treatment. But Doria's cancer never came back. Her doctor believes the MPDL-3280A – which became the FDA-approved Tecentriq – retrained her immune system to keep hunting cancer cells long after the drug left her body. Years later, Doria remained in full remission. And her doctor still couldn't fully explain why. Tecentriq costs more than $100,000 per year. And at the time of Doria's treatment, research showed that only around 13% of patients saw any benefit. Fortunately, this gamble paid off as Doria was part of that 13%. Biologics are some of the most expensive drugs in medicine. They make up nearly 40% of U.S. drug spending. And yet, they represent only about 2% of all prescriptions filled. That brings us to my point...   AI Is Turbocharging the Healthcare Sector These drugs all work. They just don't work for everyone. And unfortunately, right now, doctors can't reliably know who it works for before patients shell out all that money. This isn't a drug problem. It's a data problem. The key to success is matching the right drug to the right patient. For now, it's still trial and error. But there's a "fix"... The fix is understanding how a patient's cells respond to a drug before prescribing it. And for the first time, we have the tools to do that for every patient – not just a lucky few. It's a process known as "precision medicine." And there are healthcare companies using AI to refine this process. AI-related drug discovery needs biological data to train on. But not just any data. It needs cell-level data at massive scale – with location information intact. Companies are building the "measurement layer" that will make medicine's next big leap possible... Without it, AI models are just guessing. But with it, they can start to predict which patients will respond to a treatment before anyone sets foot in a clinic. Folks, there are a lot of worries about how AI will disrupt our daily lives... But it can also refine older, more expensive processes to open new chapters of discovery.  And healthcare is only one of the many industries jumping on board.  Our regular readers may recall we recently discussed the healthcare sector's quiet growth... However, many of these innovative drug companies can be tracked through the State Street SPDR S&P Biotech Fund (XBI). Today, XBI gets a "bullish" rating from the Power Gauge. Year to date, the fund has grown a solid 21%. And with roughly 100 "neutral" and "bullish" stocks in the fund, there are many places to consider putting money to work. So keep watching this industry as AI continues to change the way we approach medicine. Good investing, Joe Austin Market View Major Indexes and Notable Sectors     # Hld:     Bullish     Neutral       Bearish Dow 30 +1.32% 12 12 7 S&P 500 +1.42% 132 277 89 NASDAQ +1.76% 21 63 21 Small Caps +1.72% 674 1038 335 Bonds -0.07%   Health Care Equipment and Supplies +4.05% 6 50 11 — According to the Chaikin Power Bar, Small Cap stocks and Large Cap stocks are Bullish. Major indexes are mixed. *  *  *  * Sector Tracker Sector movement over the last 5 days Discretionary +6.65% Communication +3.42% Information Technology +2.15% Financial +0.88% Energy +0.74% Industrials -0.02% Staples -0.59% Health Care -0.71% Materials -0.74% Real Estate -1.27% Utilities -2.89% *  *  *  * Industry Focus Pharmaceuticals 19 38 5 Over the past 6 months, the Pharmaceuticals subsector (XPH) has outperformed the S&P 500 by 9.67%. Its Power Bar ratio which measures future potential is Very Strong, with more Bullish than Bearish stocks. It is currently ranked #7 of 21 subsectors. Top Stocks BMY Bristol-Myers Squibb Company CORT Corcept Therapeutics Incorporated ELVN Enliven Therapeutics, Inc. *  *  *  * Top Movers Gainers FSLR +10.28% COHR +9.60% LITE +9.24% ORCL +9.22% AXON +9.12% Losers MAR -6.97% FICO -6.90% EBAY -6.03% MPWR -5.73% CF -5.50% *  *  *  * Earnings report Earnings Surprises WHR Whirlpool Corporation Q2 $-0.21 Missed by $-0.26 TWST Twist Bioscience Corporation Q3 $-0.56 Missed by $-0.38 TKO TKO Group Holdings, Inc. Q2 $2.27 Beat by $1.48 ECHO EchoStar Corporation Q2 $0.14 Missed by $-2.48 LIND Lindblad Expeditions Holdings, Inc. Q2 $-0.01 Beat by $0.10 *  *  *  * You have received this e-mail as part of your subscription to PowerFeed. If you no longer want to receive e-mails from PowerFeed, click here. You're receiving this e-mail at ahmedwithnour@gmail.com. For questions about your account or to speak with customer service, call +1 (877) 697-6783 (U.S.), 9 a.m. - 5 p.m. Eastern time or e-mail info@chaikinanalytics.com. Please note: The law prohibits us from giving personalized financial advice. © 2026 Chaikin Analytics, LLC. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Chaikin Analytics, LLC. 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. www.chaikinanalytics.com. Any brokers mentioned constitute a partial list of available brokers and is for your information only. Chaikin Analytics, LLC, does not recommend or endorse any brokers, dealers, or investment advisors. Chaikin Analytics forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Chaikin Analytics, LLC (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.

Trump once publicly defended this company

The market is missing this $8 billion unicorn  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

August 04, 2026 Dear Reader, Trump fired a warning shot. And buried inside that political fight is one of the most mispriced energy stocks I’ve seen in years. I’m not talking about Exxon. Not Chevron. Not some crowded AI darling trading at 80 times earnings. I’m talking about one obscure American energy company sitting at the crossroads of AI, natural gas, and the biggest power crisis in decades. Here’s why I’m so aggressive about it... This company generated roughly $3.2 billion in operating income. Yet the entire business is valued at around $8 billion. That is crazy cheap. Especially when you consider that Wall Street is already moving in. Institutions own a huge percentage of the shares. BlackRock is in. Vanguard is in. A top value investor nearly doubled down. And still, most investors have no idea what this company is. That’s exactly the kind of setup I look for. Huge profits. Cheap valuation. A real catalyst. And almost no mainstream attention. I call it my Ultimate Stock Unicorn. Because after screening 23,281 publicly traded companies, only one passed my criteria. One. I believe this stock could become one of the biggest surprises in the market as AI’s energy demand explodes. But I’m not putting the ticker in this email. Click here to see the name, ticker, and full story behind my Ultimate Stock Unicorn. Yours in smart speculation, Karim Rahemtulla, Head Fundamental Tactician Monument Traders Alliance This email may contain paid advertisements and affiliate links. Guardian Financial Publishing may receive compensation if you click a link or make a purchase. AFAA is a publication of Guardian Financial Publishing (D/B/A) Stable Financial Publishing | Privacy Policy | Terms | Disclaimer Your American First, America Always account is active and this message was delivered as part of your current subscription. If you did not request this email or believe it was sent in error, please reply directly so our team can review your account status. Account Status and Subscription Details Your subscription is confirmed and your delivery preferences are current. You are receiving content based on the schedule and format you selected when you registered. If you need to modify your delivery window, update your email frequency, or temporarily pause communications, reply to this message and our team will process your request within one business day. Your most recent account activity has been logged and no irregular access was detected. If you did not recently sign in or modify your account preferences, please reply to this email immediately so we can investigate and secure your account. We recommend reviewing your login history regularly and changing your password if anything looks unusual. As an active subscriber, your current access includes policy briefings, legislative tracking updates, economic commentary, and periodic special reports. These are delivered on the schedule you selected during enrollment. A copy of your original registration confirmation is available upon request by replying to this message. Billing and Transaction History If you have questions about a recent charge, your next renewal date, or your current membership tier, reply to this email and a member of our billing team will pull up your account details. We maintain complete records of all transactions associated with your subscription and can provide a full billing statement upon request. For members with active paid subscriptions, billing occurs on the renewal date established at the time of your original purchase. If you need to update the payment method associated with your account, please contact our team directly by replying to this email rather than clicking links in forwarded messages. We handle all payment updates manually to safeguard against unauthorized modifications. If you believe a charge was made in error, please notify us within 30 days of the transaction date. Refund requests are reviewed on a case-by-case basis and are typically processed within five to seven business days. You will receive a confirmation email once any billing adjustment has been applied to your account. Please be aware that we will never request full payment card numbers, bank account information, or login credentials via email. Any message asking for this type of information should be treated as fraudulent and reported to our team immediately by replying to this email. Managing Your Communication Preferences We recognize that every subscriber manages their inbox differently and we respect your time. You have full control over the types of messages you receive from us. Available delivery options include daily briefings, weekly digests, breaking alerts on major policy developments only, or a temporary hold on all communications. To adjust your preferences, reply to this email with your request. Our team processes preference updates manually to ensure accuracy and prevent errors. Most changes take effect within 24 to 48 hours. If you previously submitted a preference change and it has not been reflected in your deliveries, please reply again referencing your earlier request and we will prioritize resolution. If you wish to unsubscribe entirely, you may do so using the link included at the bottom of this email. The process is simple and your request will be honored without delay. We do not use deceptive practices to prevent unsubscription and we respect every subscriber's choice. Privacy and Data Handling The personal information you provided during registration, including your name and email address, is stored securely and accessed only by authorized members of our team. We do not sell, rent, license, or disclose subscriber information to third parties for marketing or advertising purposes. Our data handling procedures are reviewed on a regular basis to ensure compliance with applicable laws and regulations. We employ industry-standard protocols for both data storage and transmission. Subscriber records are retained only for the duration necessary to fulfill your subscription obligations and satisfy any applicable legal requirements. If you would like to request a copy of the personal data we maintain on file for your account, or if you would like to request deletion of that data, please reply to this email with your request. We will process it and confirm completion within ten business days. Our privacy practices may be updated from time to time. When changes occur, subscribers will be notified via email with a clear summary of what has been revised. Continued use of our services following notification constitutes acceptance of the updated terms. Account Security The security of your account is a priority. All subscriber information is transmitted using encryption and stored on systems that are actively monitored for unauthorized access attempts. We encourage all subscribers to use strong, unique passwords and to exercise caution when responding to unsolicited messages that request personal details. If you receive a suspicious email that appears to come from American First, America Always, please forward it to our team for review. We will examine the message and confirm whether it is legitimate. Do not click links or open attachments in messages you are uncertain about until you have verified their authenticity with us. For added protection, we recommend reviewing your account settings on a regular basis to verify that your contact details and communication preferences are accurate. If you discover any discrepancies or information that appears incorrect, reply to this email and our support team will assist you in resolving the issue. Contacting Our Team Our support team is available Monday through Friday during standard business hours. We strive to respond to all subscriber inquiries within one business day. For urgent matters related to account security or unauthorized access, we prioritize expedited response times. To contact our team, reply directly to this email. Please include your full name and the email address linked to your subscription so we can locate your account records efficiently. If you are writing on behalf of another subscriber, please include written authorization from the account holder. We genuinely value feedback from our subscribers regarding our content, communication frequency, and the overall subscriber experience. Every reply is reviewed by a member of our team and your input directly informs how we refine and improve our service. Content and Editorial Disclaimer The information delivered through American First, America Always is provided for educational and informational purposes. The views expressed represent the analysis and commentary of our editorial team at the time of publication. Political, economic, and legislative conditions are subject to rapid change and readers are encouraged to verify information independently and consult with qualified professionals where appropriate. Our editorial staff makes every reasonable effort to ensure accuracy and fairness in the information we publish. However, we cannot guarantee that all details remain current following delivery. If you identify an error or inaccuracy in any of our content, please notify us by replying to this email and we will issue a correction as quickly as possible. Thank you for being an active member of the American First, America Always community. We value your trust, your time, and your engagement. If there is anything we can do to improve your experience as a subscriber, please do not hesitate to reach out by replying to this message.     Update your email preferences or unsubscribe here © 2026 Stable Financial Publications 1013 Centre Road Suite 403-D Wilmington, DE 19805, United States